We performed proof-of-concept studies to investigate whether TLR2 and TLR9 intrabodies that we generated [24,25] could inhibit pancreatic cancer cell growth, decrease inflammatory markers, and induce apoptosis. Here, TLR9 is linked to familial pancreatic carcinoma.